Correction: Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand

被引：0
|
作者：
Junhui Yu
Kui Yang
Jianbao Zheng
Wei Zhao
Xuejun Sun
机构：
[1] First Affiliated Hospital of Xi’an Jiaotong University,Department of General Surgery
来源：
Cancer Gene Therapy | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：871 / 872
页数：1
相关论文
共 50 条
  • [1] Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand
    Junhui Yu
    Kui Yang
    Jianbao Zheng
    Wei Zhao
    Xuejun Sun
    Cancer Gene Therapy, 2021, 28 : 590 - 601
  • [2] Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand
    Yu, Junhui
    Yang, Kui
    Zheng, Jianbao
    Zhao, Wei
    Sun, Xuejun
    CANCER GENE THERAPY, 2021, 28 (06) : 590 - 601
  • [3] Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand (vol 28, pg 590, 2021)
    Yu, Junhui
    Yang, Kui
    Zheng, Jianbao
    Zhao, Wei
    Sun, Xuejun
    CANCER GENE THERAPY, 2022, 29 (06) : 871 - 872
  • [4] A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor
    Narayanan, Anila Kutty
    Surendran, Sudhindran
    Balakrishnan, Dinesh
    Gopalakrishnan, Unnikrishnan
    Malick, Shweta
    Valsan, Arun
    Philips, Abby Cyriac
    Watson, Christopher
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2024, 19 (03) : 225 - 233
  • [5] The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid
    Walters, J. R. F.
    Johnston, I. M.
    Nolan, J. D.
    Vassie, C.
    Pruzanski, M. E.
    Shapiro, D. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (01) : 54 - 64
  • [6] Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand
    Ohno, Tomohiko
    Shirakami, Yohei
    Shimizu, Masahito
    Kubota, Masaya
    Sakai, Hiroyasu
    Yasuda, Yoichi
    Kochi, Takahiro
    Tsurumi, Hisashi
    Moriwaki, Hisataka
    CANCER LETTERS, 2012, 323 (02) : 215 - 222
  • [7] Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand
    Ohno, Tomohiko
    Shimizu, Masahito
    Kubota, Masaya
    Sakai, Hiroyasu
    Moriwaki, Hisataka
    CANCER RESEARCH, 2012, 72
  • [8] The cancerogenic potential of primary human Cholangioracinoma cells is inhibited by Obeticholic Acid, a Farnesoid X Receptor (FXR) agonist
    Di Matteo, S.
    Nevi, L.
    Costantini, D.
    Colantonio, M.
    Giulitti, F.
    Napoletano, C.
    Safarikia, S.
    Manzi, E.
    Derose, A. M.
    Melandro, F.
    Bragazzi, M. C.
    Grazi, G.
    Berloco, P. B.
    Giuliante, F.
    Carpino, G.
    Cardinale, V.
    Gaudio, E.
    Alvaro, D.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (01) : 22 - 23
  • [9] Process Research and Impurity Control Strategy for Obeticholic Acid, a Farnesoid X Receptor Agonist
    Feng, Wei-Dong
    Zhuo, Song-Ming
    Zhang, Fu-Li
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2019, 23 (09) : 1979 - 1989
  • [10] AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC
    Kowdley, K. V.
    Jones, D.
    Luketic, V.
    Chapman, R.
    Burroughs, A.
    Hirschfield, G.
    Poupon, R.
    Schramm, C.
    Vincent, C.
    Rust, C.
    Pares, A.
    Mason, A.
    Sciacca, C.
    Beecher-Jones, T.
    Bohm, O.
    Castelloe, E.
    Pruzanski, M.
    Shapiro, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S13 - S13
12345